Strides Arcolab is currently trading at Rs. 891.70, up by 2.95 points or 0.33% from its previous closing of Rs. 888.75 on the BSE.
The scrip opened at Rs. 894.00 and has touched a high and low of Rs. 907.85 and Rs. 835.00 respectively. So far 135958 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 999.00 on 05-Dec-2014 and a 52 week low of Rs. 343.80 on 26-Feb-2014.
Last one week high and low of the scrip stood at Rs. 964.15 and Rs. 881.00 respectively. The current market cap of the company is Rs. 5297.77 crore.
The promoters holding in the company stood at 27.67% while Institutions and Non-Institutions held 46.79% and 25.54% respectively.
Strides Arcolab has received approval from the United States Food & Drug Administration (USFDA) for Calcitriol Softgel Capsules, 0.25mcg and 0.5mcg. Calcitriol is a Vitamin D capsule, used in patients with kidney disease who can't make enough of the active form of Vitamin D. This medication is also used to prevent and treat certain types of calcium/phosphorus/parathyroid problems that can happen with long-term kidney dialysis or hypoparathyroidism. Calcitriol is usually used along with specific diet recommendations and sometimes other medications.
According to IMS data, the US market for generic Calcitriol Softgel Capsules is around $50 million, with only three players having approval for both the strengths of Calcitriol. The product will be manufactured at the company’s Oral dosage facility at Bangalore and marketed by Strides in the US Market.
Strides Arcolab is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures wide range of IP-lead niche pharmaceutical products with an emphasis on sterile injectables.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: